enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Last trade$1.71
Day change-$0.18 (-9.52%)
Day range$1.68 – $1.97
Volume1,343,641
Market cap$127M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$126.66M
Price / earnings
—
Price / book
0.55×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.82×
Profitability
Earnings per share
-$1.95
Return on assets
-45.21%
Return on equity
-56.61%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.11×
Current ratio
10.21×
Quick ratio
10.21×
Cash ratio
1.51×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$104M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ENGN, quarterly periods
Line item
Q3 FY2026 Jul 31, 2026
Q2 FY2026 Apr 30, 2026
Q1 FY2026 Jan 31, 2026
Q4 FY2025 Oct 31, 2025
Q3 FY2025 Jul 31, 2025
Q2 FY2025 Apr 30, 2025
Q1 FY2025 Jan 31, 2025
Q4 FY2024 Oct 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$13.92M
$9.77M
$8.93M
$7.76M
$7.37M
$6.92M
$6.64M
$6.18M
Research and development
$20.09M
$22.2M
$22.26M
$31.72M
$22.58M
$20.21M
$19.97M
$11.27M
Total operating expenses
$34.01M
$31.97M
$31.19M
$39.48M
$29.95M
$27.12M
$26.61M
$17.46M
Operating income
-$34.01M
-$31.97M
-$31.19M
-$39.48M
-$29.95M
-$27.12M
-$26.61M
-$17.46M
Interest expense
-$843K
-$745K
-$732K
-$750K
-$758K
-$734K
-$752K
-$756K
Income before taxes
-$32.5M
-$30.23M
-$29.75M
-$38.38M
-$28.75M
-$25.58M
-$24.6M
-$15.28M
Income taxes
$0
$0
$0
-$497K
$239K
$240K
$18K
$19K
Net income
-$32.5M
-$30.23M
-$29.75M
-$37.88M
-$28.99M
-$25.82M
-$24.62M
-$15.3M
Net income attributable to common shareholders
-$32.5M
-$30.23M
-$29.75M
-$37.88M
-$28.99M
-$25.82M
-$24.62M
-$15.3M
EBITDA
-$33.84M
-$31.79M
-$31M
-$39.31M
-$29.82M
-$27.02M
-$26.51M
-$17.37M
Basic earnings per share
-$0.47
-$0.43
-$0.44
-$0.74
-$0.57
-$0.51
-$0.48
-$0.35
Diluted earnings per share
-$0.47
-$0.43
-$0.44
-$0.74
-$0.57
-$0.51
-$0.48
-$0.35
Recent news
Company coverage with links to the original publishers.
Junshi Biosciences announced that China's NMPA has accepted new drug applications for JS001sc, a subcutaneous formulation of toripalimab (anti-PD-1 monoclonal antibody), across 12 tumor indications. The Phase 3 clinical trial demonstrated non-inferior drug exposure and comparable efficacy and safety compared to intravenous administration, marking the first domestic anti-PD-1 subcutaneous formulation to reach the marketing application stage.
Shares of AppLovin Corporation (NASDAQ: APP) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results.
AppLovin reported quarterly earnings of 49 cents per share which beat the analyst consensus estimate of 36 cents. The company reported quarterly sales of $953.26 million, beating the analyst consensus estimate of $928.17 million.
AppLovin shares jumped 22.3% to $57.30 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers
China Natural Resources, Inc. (NASDAQ: CHNR) gained 409% to $5.60 in pre-market trading after gaining around 10% on Wednesday.
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA) shares jumped 70.2% to $1.89 in pre-market trading after surging around 19% on Wednesday.
SoundHound AI, Inc. (NASDAQ: SOUN) gained 69.8% to $3.83 in pre-market trading. According to data from Benzinga Pro, BlackRock reported a 5.6% passive stake in SoundHound AI after the market close. Traders also appear to be circling a filing from Nvidia in which the ...
U.S. stock futures were higher this morning, with the Dow futures trading higher by around 70 points on Thursday.
Shares of Cisco Systems, Inc. (NASDAQ: CSCO) fell in today’s pre-market trading following second-quarter results.
Cisco reported better-than-expected second-quarter financial results but issued weak full-year 2024 guidance. The company also announced a restructuring plan to cut approximately 5% of its global workforce.
Cisco Systems shares fell 5.2% to $47.68 in pre-market trading.
Here are some big stocks recording losses in today’s pre-market trading session.
Nu Skin Enterprises, Inc. (NYSE: NUS) shares dipped 24% to $13.25 ...
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Wednesday.
The Dow traded up 0.11% to 38,313.27 while the NASDAQ rose 0.70% to 15,765.18. The S&P 500 also rose, gaining, 0.49% to 4,977.43.
Check This Out: Snap, American Express And 2 Other Stocks Insiders Are Selling
Leading and Lagging Sectors
Industrials shares rose by 1.1% on Wednesday.
In trading on Wednesday, consumer staples shares fell by 0.6%.
Top Headline
Crude oil inventories in the U.S. surged by 12.018 million barrels in the week ending Feb. 9, compared to market estimates of a 2.56 million rise.
Equities Trading UP
enGene Holdings Inc. (NASDAQ: ENGN) shares shot up 83% to $13.95. The company’s CEO Jason Hanson is resigning due to personal family and health reasons, though he will continue to support the company as a strategic advisor after a successor is appointed. Concurrently, enGene announced a private placement of 20 million common shares at $10.00 per share, representing a 31% premium over the previous day’s closing price.
Shares of Lyft, Inc. (NASDAQ:
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list its financial arm in October 2025.
Sony Group reported third-quarter FY23 sales growth of 22% year-on-year to $25.34 billion (¥3.75 trillion), beating the consensus of $24.62 billion. Adjusted EPS of $1.99 beat the consensus of $1.65.
Sony revised its FY23 sales outlook to $86.62 billion (¥12.4 trillion), down from a prior forecast of ¥12.3 trillion versus the consensus of $87.32 billion.
Sony Group shares fell 6.3% to $89.86 on Wednesday.
Here are some other stocks moving in today's mid-day session.
Gainers
Datasea Inc. (NASDAQ: DTSS) shares jumped 1,173% to $18.59. On Tuesday, Datasea posted a narrower second-quarter loss.
Earlyworks Co., Ltd. (NASDAQ: ELWS) surged 416% to $2.35 on two passive stakes.
enGene Holdings Inc. (NASDAQ: ENGN) jumped 95.5% to $14.90. The company’s CEO Jason Hanson is resigning due to personal family and health reasons, though he will continue to support the company as a strategic advisor after a successor is appointed. Concurrently, enGene announced a private placement of 20 million common shares at $10.00 per share, representing a 31% premium over the previous day’s closing price.
Cineverse Corp. (NASDAQ: CNVS) surged 92.9% to $2.9899. Cineverse announced forthcoming launch of AI-powered movie search platform cineSearch.
Cheche Group Inc. (NASDAQ: CCG) gained 74.3% to $5.49.
MGO Global, Inc. (NASDAQ: MGOL) rose 66% to $0.6647.
Cogent Biosciences, Inc. (NASDAQ: COGT) surged 62.7% to $8.89.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) gained 35% to $1.29 after the company announced it received the first ever U.S. Patent approval for an orbiting blood oxygenation delivery system, a core technology of the INSPIRA ART500 device.
Lyft, Inc. (NASDAQ: LYFT) shares gained 34.3% to $16.29 after the company reported fourth-quarter sales of $1.22 billion and gross bookings of $3.7 ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Aug 3, 2015
$0.1263
Aug 7, 2015
recurring
Jul 1, 2015
$0.1251
Jul 8, 2015
recurring
Jun 1, 2015
$0.1251
Jun 5, 2015
unknown
May 1, 2015
$0.1219
May 7, 2015
recurring
Apr 1, 2015
$0.1294
Apr 8, 2015
recurring
Stock splits
Historical share-structure events and their execution dates.